Back to Search
Start Over
Association of Body Mass Index With Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
- Source :
- J Cardiovasc Pharmacol Ther
- Publication Year :
- 2021
-
Abstract
- Background: Only limited data are available that address the association between body mass index (BMI) and clinical outcomes in patients with heart failure with reduced ejection fraction who are receiving sacubitril/valsartan. Methods: We performed a retrospective multi-center cohort study in which we compared 3 body mass index groups (normal, overweight and obese groups) in patients with heart failure with reduced ejection fraction receiving sacubitril/valsartan. The follow-up period was at least 1 year. Propensity score weighting was performed. The primary outcomes were hospitalization for heart failure and all-cause mortality. Results: Of the 721 patients in the original cohort, propensity score weighting generated a cohort of 540 patients in 3 groups: normal weight (n = 78), overweight (n = 181), and obese (n = 281). All baseline characteristics were well-balanced between 3 groups after propensity score weighting. Among our results, we found no significant differences in hospitalization for heart failure (normal weight versus overweight: average hazard ratio [AHR] 1.29, 95% confidence interval [CI] = 0.76-2.20, P = 0.35; normal weight versus obese: AHR 1.04, 95% CI = 0.63-1.70, P = 0.88; overweight versus obese groups: AHR 0.81, 95% CI = 0.54-1.20, P = 0.29) or all-cause mortality (normal weight versus overweight: AHR 0.99, 95% CI = 0.59-1.67, P = 0.97; normal weight versus obese: AHR 0.87, 95% CI = 0.53-1.42, P = 0.57; overweight versus obese: AHR 0.87, 95% CI = 0.58-1.32, P = 0.52). Conclusion: We identified no significant associations between BMI and clinical outcomes in patients diagnosed with heart failure with a reduced ejection fraction who were treated with sacubitril/valsartan. A large-scale study should be performed to verify these results.
- Subjects :
- Male
medicine.medical_specialty
030204 cardiovascular system & hematology
Sacubitril
Article
Body Mass Index
Cohort Studies
03 medical and health sciences
Angiotensin Receptor Antagonists
0302 clinical medicine
Risk Factors
Internal medicine
Cause of Death
medicine
Humans
Pharmacology (medical)
Aged
Retrospective Studies
Pharmacology
Aged, 80 and over
Heart Failure
Ejection fraction
business.industry
Aminobutyrates
Biphenyl Compounds
Stroke Volume
Middle Aged
Overweight
West Virginia
medicine.disease
Obesity
Drug Combinations
Valsartan
Heart failure
Cardiology
Cardiology and Cardiovascular Medicine
business
Body mass index
030217 neurology & neurosurgery
Obesity paradox
Sacubitril, Valsartan
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- J Cardiovasc Pharmacol Ther
- Accession number :
- edsair.doi.dedup.....c6c222ab777da0e57da5e1429186b612